Eisai seeks early retirees, production and R&D restructuring to cut costs
This article was originally published in Scrip
Executive Summary
Eisai is taking a series of new steps to reduce costs and employee numbers in three areas as it looks to adapt to life after the loss of exclusivity for former blockbuster Aricept (donepezil) for Alzheimer's disease.